All In Biotech

Drug Trial Radar · NCT07093333

A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Autoantibody-Associated Psychiatric Disease

A Phase 2a, Open-label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of ART5803 in Participants With Anti-NMDAR Encephalitis and AntiNMDAR Autoantibody-Associated Psychiatric Disease

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

May 15, 2026

Primary completion

Nov 30, 2027

Study completion May 30, 2028

Sponsor

Lead sponsor
Arialys Australia Pty LtdIndustry
Sponsor type
Industry
Collaborators
Arialys Therapeutics; Seoul National University Hospital
First posted
Jul 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, preliminary efficacy and pharmacokinetics (PK) of ART5803 in adult participants with a confirmed diagnosis of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis (ANRE) or anti-NMDAR autoantibody-associated psychiatric disease

Conditions

  • Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE)
  • Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease
  • Autoimmune Encephalitis

Interventions

  • ART5803Drug

    A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor. 1. Sentinel participants: 30 mg/kg 2. Subsequent participants: up to 60 mg/kg 3. Schedule: Q1W for 4 doses then Q2W for 4 doses

  • ART5803-Cohort DDrug

    A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor. Participants receive ART5803 by intravenous infusion once a week for 4 weeks, then every 2 weeks for 8 weeks, for a total of 8 doses. Sentinel participants receive 30 mg per kg. Additional participants may receive up to 60 mg per kg based on Safety Review Committee guidance.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of ART5803Time frame: 26 weeks
  2. To assess the safety and tolerability of ART5803Time frame: 26 weeks
  3. To assess the safety and tolerability of ART5803Time frame: 26 weeks
  4. To assess the safety and tolerability of ART5803Time frame: 26 weeks
  5. To assess the safety and tolerability of ART5803Time frame: 26 weeks
  6. To assess the safety and tolerability of ART5803Time frame: 26 weeks
  7. To assess the safety and tolerability of ART5803Time frame: 26 weeks
  8. To assess the safety and tolerability of ART5803Time frame: 26 weeks
  9. To assess the safety and tolerability of ART5803Time frame: 26 weeks
  10. To assess the safety and tolerability of ART5803Time frame: 26 weeks
  11. To assess the safety and tolerability of ART5803Time frame: 26 weeks
  12. To assess the safety and tolerability of ART5803Time frame: 26 weeks
  13. To assess the safety and tolerability of ART5803Time frame: 26 weeks
  14. To assess the safety and tolerability of ART5803Time frame: 26 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.